You are currently on the new version of our website. Access the old version .

776 Results Found

  • Review
  • Open Access
86 Citations
19,409 Views
13 Pages

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

  • Shaofeng Deng,
  • Hui Liang,
  • Pin Chen,
  • Yuwan Li,
  • Zhaoyao Li,
  • Shuangqi Fan,
  • Keke Wu,
  • Xiaowen Li,
  • Wenxian Chen and
  • Jinding Chen
  • + 1 author

With the accumulation of mutations in SARS-CoV-2 and the continuous emergence of new variants, the importance of developing safer and effective vaccines has become more prominent in combating the COVID-19 pandemic. Both traditional and genetically en...

  • Review
  • Open Access
12 Citations
8,827 Views
20 Pages

Over the past several decades, viral vector-based vaccines have emerged as some of the most versatile and potent platforms in modern vaccinology. Their capacity to deliver genetic material encoding target antigens directly into host cells enables str...

  • Review
  • Open Access
37 Citations
10,713 Views
18 Pages

Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design

  • Onur Kaynarcalidan,
  • Sara Moreno Mascaraque and
  • Ingo Drexler

26 November 2021

Various vaccinia virus (VACV) strains were applied during the smallpox vaccination campaign to eradicate the variola virus worldwide. After the eradication of smallpox, VACV gained popularity as a viral vector thanks to increasing innovations in gene...

  • Article
  • Open Access
8 Citations
2,924 Views
9 Pages

Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on COVID-19 Infection in Kidney Transplant Recipients

  • Napun Sutharattanapong,
  • Sansanee Thotsiri,
  • Surasak Kantachuvesiri and
  • Punlop Wiwattanathum

8 April 2022

The coronavirus virus disease 2019 (COVID-19) pandemic has impacted the global healthcare system. In Thailand, the first and most available vaccines were inactivated and viral vector vaccines. We reported the impact of those vaccines in preventing se...

  • Article
  • Open Access
73 Citations
11,921 Views
13 Pages

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

  • Sitthichai Kanokudom,
  • Suvichada Assawakosri,
  • Nungruthai Suntronwong,
  • Chompoonut Auphimai,
  • Pornjarim Nilyanimit,
  • Preeyaporn Vichaiwattana,
  • Thanunrat Thongmee,
  • Ritthideach Yorsaeng,
  • Donchida Srimuan and
  • Yong Poovorawan
  • + 4 authors

6 January 2022

The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the s...

  • Review
  • Open Access
35 Citations
7,516 Views
16 Pages

Viral vectors and viral vaccines are invaluable tools in prevention and treatment of diseases. Many infectious diseases are controlled using vaccines designed from subunits or whole viral structures, whereas other genetic diseases and cancers are bei...

  • Article
  • Open Access
22 Citations
6,351 Views
13 Pages

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

  • Jira Chansaenroj,
  • Nungruthai Suntronwong,
  • Sitthichai Kanokudom,
  • Suvichada Assawakosri,
  • Ritthideach Yorsaeng,
  • Preeyaporn Vichaiwattana,
  • Sirapa Klinfueng,
  • Lakana Wongsrisang,
  • Donchida Srimuan and
  • Yong Poovorawan
  • + 5 authors

3 July 2022

Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to...

  • Case Report
  • Open Access
3 Citations
2,754 Views
11 Pages

Thyroid Eye Disease as Initial Manifestation of Graves’ Disease Following Viral Vector SARS-CoV-2 Vaccine: Report of a Case and Review of the Literature

  • Anastasia K. Armeni,
  • Georgios Κ. Markantes,
  • Alexandra Stathopoulou,
  • Katerina Saltiki,
  • Petros Zampakis,
  • Stelios F. Assimakopoulos and
  • Marina A. Michalaki

10 October 2023

COVID-19, a contagious disease caused by the novel coronavirus SARS-CoV-2, emerged in 2019 and quickly became a pandemic, infecting more than 700 million people worldwide. The disease incidence, morbidity and mortality rates have started to decline s...

  • Review
  • Open Access
48 Citations
9,383 Views
27 Pages

18 November 2020

Viral vectors can generate high levels of recombinant protein expression providing the basis for modern vaccine development. A large number of different viral vector expression systems have been utilized for targeting viral surface proteins and tumor...

  • Review
  • Open Access
396 Citations
29,238 Views
18 Pages

Developments in Viral Vector-Based Vaccines

  • Takehiro Ura,
  • Kenji Okuda and
  • Masaru Shimada

29 July 2014

Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last s...

  • Review
  • Open Access
17 Citations
11,732 Views
20 Pages

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

  • Aline Baldo,
  • Amaya Leunda,
  • Nicolas Willemarck and
  • Katia Pauwels

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines ag...

  • Review
  • Open Access
26 Citations
7,176 Views
19 Pages

Viral Vector Vaccines against Bluetongue Virus

  • Luis Jiménez-Cabello,
  • Sergio Utrilla-Trigo,
  • Eva Calvo-Pinilla,
  • Sandra Moreno,
  • Aitor Nogales,
  • Javier Ortego and
  • Alejandro Marín-López

Bluetongue virus (BTV), the prototype member of the genus Orbivirus (family Reoviridae), is the causative agent of an important livestock disease, bluetongue (BT), which is transmitted via biting midges of the genus Culicoides. To date, up to 29 sero...

  • Review
  • Open Access
26 Citations
7,546 Views
16 Pages

Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer

  • Laura Seclì,
  • Guido Leoni,
  • Valentino Ruzza,
  • Loredana Siani,
  • Gabriella Cotugno,
  • Elisa Scarselli and
  • Anna Morena D’Alise

22 November 2023

The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing the adverse events. Over recent years, there has been a r...

  • Review
  • Open Access
3,234 Views
18 Pages

Trends in Viral Vector-Based Vaccines for Tuberculosis: A Patent Review (2010–2023)

  • Lana C. Santos,
  • Antônio Márcio Santana Fernandes,
  • Izabel Almeida Alves,
  • Mairim Russo Serafini,
  • Leandra da Silva e Silva,
  • Humberto Fonseca de Freitas,
  • Luciana C. C. Leite and
  • Carina C. Santos

2 August 2024

Tuberculosis (TB) is an ancient global public health problem. Several strategies have been applied to develop new and more effective vaccines against TB, from attenuated or inactivated mycobacteria to recombinant subunit or genetic vaccines, includin...

  • Article
  • Open Access
54 Citations
7,026 Views
15 Pages

19 August 2021

Vaccine hesitancy (VH) may be significant in jeopardizing efforts to mass containment of COVID-19. A cross-sectional survey was carried out on a sample of 2667 Italian college students, before the COVID-19 vaccines became available for this age group...

  • Review
  • Open Access
2 Citations
4,732 Views
13 Pages

14 January 2025

Over the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biol...

  • Review
  • Open Access
61 Citations
8,850 Views
21 Pages

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

  • Vivek P. Chavda,
  • Rajashri Bezbaruah,
  • Mansi Athalye,
  • Palak K. Parikh,
  • Abu Sufiyan Chhipa,
  • Snehal Patel and
  • Vasso Apostolopoulos

6 April 2022

The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of human coronavirus (CoV) that is held accountable for the current “coronavirus disease 2019 (COVID-19)” pandemic. In the past two decades...

  • Review
  • Open Access
69 Citations
10,556 Views
31 Pages

Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats

  • Sophia M. Vrba,
  • Natalie M. Kirk,
  • Morgan E. Brisse,
  • Yuying Liang and
  • Hinh Ly

13 November 2020

Vaccination is arguably the most cost-effective preventative measure against infectious diseases. While vaccines have been successfully developed against certain viruses (e.g., yellow fever virus, polio virus, and human papilloma virus HPV), those ag...

  • Article
  • Open Access
19 Citations
8,252 Views
21 Pages

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant

  • Shailbala Singh,
  • Pramod N. Nehete,
  • Guojun Yang,
  • Hong He,
  • Bharti Nehete,
  • Patrick W. Hanley,
  • Michael A. Barry and
  • K. Jagannadha Sastry

10 October 2014

Gene-based vaccination strategies, specifically viral vectors encoding vaccine immunogens are effective at priming strong immune responses. Mucosal routes offer practical advantages for vaccination by ease of needle-free administration, and immunogen...

  • Review
  • Open Access
6 Citations
4,451 Views
23 Pages

12 February 2022

The persistent expansion of the coronavirus disease 2019 (COVID-19) global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires the rapid development of safe and effective countermeasures to reduce transmission, mo...

  • Communication
  • Open Access
1 Citations
1,743 Views
9 Pages

A Simple and Versatile Method for Ex Vivo Monitoring of Goat Vaginal Mucosa Transduction by Viral Vector Vaccines

  • Sergio Minesso,
  • Amienwanlen Eugene Odigie,
  • Valentina Franceschi,
  • Camilla Cotti,
  • Sandro Cavirani,
  • Maria Tempesta and
  • Gaetano Donofrio

29 July 2024

Goat may represent a valid large animal model for human pathogens and new vaccines testing. Appropriate vaccine administration is a critical component of a successful immunization program. The wrong route of administration may reduce the efficacy of...

  • Article
  • Open Access
40 Citations
9,825 Views
17 Pages

Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus

  • César López-Camacho,
  • Young Chan Kim,
  • Joshua Blight,
  • Marcos Lazaro Moreli,
  • Eduardo Montoya-Diaz,
  • Juha T Huiskonen,
  • Beate Mareike Kümmerer and
  • Arturo Reyes-Sandoval

3 April 2019

Chikungunya virus (CHIKV) has caused extensive outbreaks in several countries within the Americas, Asia, Oceanic/Pacific Islands, and Europe. In humans, CHIKV infections cause a debilitating disease with acute febrile illness and long-term polyarthra...

  • Article
  • Open Access
6 Citations
2,708 Views
14 Pages

Immunogenicity and Protective Efficacy of a Recombinant Pichinde Viral-Vectored Vaccine Expressing Influenza Virus Hemagglutinin Antigen in Pigs

  • Sushmita Kumari,
  • Jayeshbhai Chaudhari,
  • Qinfeng Huang,
  • Phillip Gauger,
  • Marcelo Nunes De Almeida,
  • Yuying Liang,
  • Hinh Ly and
  • Hiep L. X. Vu

26 August 2022

Influenza A virus of swine (IAV-S) is an economically important swine pathogen. The IAV-S hemagglutinin (HA) surface protein is the main target for vaccine development. In this study, we evaluated the feasibility of using the recombinant tri-segmente...

  • Article
  • Open Access
8 Citations
2,476 Views
9 Pages

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization

  • Sansanee Thotsiri,
  • Rungtiwa Sittiudomsuk,
  • Napun Sutharattanapong,
  • Surasak Kantachuvesiri and
  • Punlop Wiwattanathum

10 October 2022

The mortality rate after novel coronavirus infection, which causes severe acute respiratory distress syndrome (SARS-CoV-2), is much higher in kidney transplant recipients (KTRs) compared to the general population. Seroconversion after vaccination is...

  • Article
  • Open Access
8 Citations
3,161 Views
14 Pages

Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus

  • Young Chan Kim,
  • Arlen-Celina Lücke,
  • César López-Camacho,
  • Beate Mareike Kümmerer and
  • Arturo Reyes-Sandoval

Mayaro virus (MAYV) is an emerging alphavirus causing acute febrile illness associated with chronic polyarthralgia. Although MAYV is currently restricted to tropical regions in South America around the Amazon basin, it has the potential to spread glo...

  • Article
  • Open Access
5 Citations
5,409 Views
15 Pages

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma

  • Georges Katoul Al Rahbani,
  • Christina Woopen,
  • Marie Dunsche,
  • Undine Proschmann,
  • Tjalf Ziemssen and
  • Katja Akgün

19 June 2024

Disease-modifying therapies (DMTs) impact the cellular immune response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (pwMS). In this study, we aim to elucidate the characteristics of...

  • Review
  • Open Access
2 Citations
4,759 Views
19 Pages

8 February 2022

Avian orthoavulaviruses type-1 (AOaV-1) have recently transitioned from animal vaccine vector to a bona fide vaccine delivery vehicle in human. Owing to induction of robust innate and adaptive immune responses in mucus membranes in both birds and mam...

  • Article
  • Open Access
1 Citations
2,032 Views
26 Pages

Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields

  • Sven Göbel,
  • Tilia Zinnecker,
  • Ingo Jordan,
  • Volker Sandig,
  • Andrea Vervoort,
  • Jondavid de Jong,
  • Jean-Simon Diallo,
  • Peter Satzer,
  • Manfred Satzer and
  • Yvonne Genzel
  • + 1 author

16 July 2025

Background: Modern viral vector production needs to consider process intensification for higher yields from smaller production volumes. However, innate antiviral immunity triggered in the producer cell may limit virus replication. While commonly used...

  • Article
  • Open Access
4 Citations
3,168 Views
21 Pages

We have shown that manipulation of IL-13 and STAT6 signaling at the vaccination site can lead to different innate lymphoid cell (ILC)/dendritic cell (DC) recruitment, resulting in high avidity/poly-functional T cells and effective antibody differenti...

  • Article
  • Open Access
14 Citations
5,060 Views
27 Pages

Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector

  • Irina Isakova-Sivak,
  • Ekaterina Stepanova,
  • Victoria Matyushenko,
  • Sergei Niskanen,
  • Daria Mezhenskaya,
  • Ekaterina Bazhenova,
  • Elena Krutikova,
  • Tatiana Kotomina,
  • Polina Prokopenko and
  • Larisa Rudenko
  • + 4 authors

18 July 2022

The COVID-19 pandemic emerged in 2020 and has caused an unprecedented burden to all countries in the world. SARS-CoV-2 continues to circulate and antigenically evolve, enabling multiple reinfections. To address the issue of the virus antigenic variab...

  • Review
  • Open Access
2 Citations
2,676 Views
15 Pages

Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections

  • Njabulo Mnyandu,
  • Ridhwaanah Jacobs,
  • Patrick Arbuthnot and
  • Mohube Betty Maepa

Over 80% of the world’s deadliest pandemics are caused by viral infections, and vaccination remains the most effective way to prevent these infections from spreading. Since the discovery of the first vaccine over two centuries ago, several vacc...

  • Article
  • Open Access
23 Citations
6,852 Views
12 Pages

Fowl Adenovirus 4 (FAdV-4)-Based Infectious Clone for Vaccine Vector Development and Viral Gene Function Studies

  • Yanlong Pei,
  • Juan C. Corredor,
  • Bryan D. Griffin,
  • Peter J. Krell and
  • Éva Nagy

24 February 2018

Fowl adenovirus 4 (FAdV-4) is associated with economically important poultry diseases. Recent studies of fully sequenced genomes of FAdV-4 isolates suggest potential genomic regions associated with virulence and amenable for manipulation and vector d...

  • Article
  • Open Access
2 Citations
3,512 Views
14 Pages

30 October 2024

Liquid formulations have been successfully used in many viral vector vaccines including influenza (Flu), hepatitis B, polio (IPV), Ebola, and COVID-19 vaccines. The main advantage of liquid formulations over lyophilized formulations is that they are...

  • Review
  • Open Access
8 Citations
5,112 Views
16 Pages

19 September 2019

Extensive research on generating an efficient HIV vaccine is ongoing. A major aim of HIV vaccines is the induction of long-lasting, broadly neutralizing antibodies (bnAbs) that can confer sterile immunity for a prolonged period of time. Several strat...

  • Article
  • Open Access
2,837 Views
18 Pages

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms

  • Wafa Ben Hamouda,
  • Mariem Hanachi,
  • Sonia Ben Hamouda,
  • Wafa Kammoun Rebai,
  • Adel Gharbi,
  • Amor Baccouche,
  • Jihene Bettaieb,
  • Oussema Souiai,
  • Mohamed Ridha Barbouche and
  • Chaouki Benabdessalem
  • + 1 author

Background: Vaccination constitutes the best strategy against COVID-19. In Tunisia, seven vaccines standing for the three main platforms, namely RNA, viral vector, and inactivated vaccines, have been used to vaccinate the population at a large scale....

  • Review
  • Open Access
90 Citations
8,782 Views
29 Pages

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

  • Kailash C. Petkar,
  • Suyash M. Patil,
  • Sandip S. Chavhan,
  • Kan Kaneko,
  • Krutika K. Sawant,
  • Nitesh K. Kunda and
  • Imran Y. Saleem

The development of vaccines is one of the most significant medical accomplishments which has helped to eradicate a large number of diseases. It has undergone an evolutionary process from live attenuated pathogen vaccine to killed whole organisms or i...

  • Article
  • Open Access
1,800 Views
14 Pages

23 December 2024

Background: Live viral vector-based vaccines are known to elicit strong immune responses, but their use can be limited by anti-vector immunity. Here, we analyzed the immunological responses of a live-attenuated recombinant Pichinde virus (PICV) vecto...

  • Review
  • Open Access
39 Citations
10,685 Views
12 Pages

Vaccines against Botulism

  • Grace Sundeen and
  • Joseph T. Barbieri

2 September 2017

Botulinum neurotoxins (BoNT) cause the flaccid paralysis of botulism by inhibiting the release of acetylcholine from motor neurons. There are seven serotypes of BoNT (A-G), with limited therapies, and no FDA approved vaccine for botulism. An investig...

  • Article
  • Open Access
1 Citations
2,737 Views
12 Pages

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine

  • Auchara Tangsathapornpong,
  • Sira Nanthapisal,
  • Kanassanan Pontan,
  • Pornumpa Bunjoungmanee,
  • Yamonbhorn Neamkul,
  • Arthit Boonyarangkul,
  • Supattra Wanpen,
  • Waraphon Fukpho,
  • Sumana Jitpokasem and
  • Peera Jaru-Ampornpan

27 February 2023

The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID...

  • Review
  • Open Access
28 Citations
6,192 Views
16 Pages

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

  • Olga Vladimirovna Orlova,
  • Dina Viktorovna Glazkova,
  • Elena Vladimirovna Bogoslovskaya,
  • German Alexandrovich Shipulin and
  • Sergey Mikhailovich Yudin

13 September 2022

Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its p...

  • Review
  • Open Access
86 Citations
19,936 Views
17 Pages

Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines

  • Ger T. Rijkers,
  • Nynke Weterings,
  • Andres Obregon-Henao,
  • Michaëla Lepolder,
  • Taru S. Dutt,
  • Frans J. van Overveld and
  • Marcela Henao-Tamayo

3 August 2021

Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which has reached pandemic proportions. A number of effective vaccines have been produced, including mRNA vaccines and viral vecto...

  • Review
  • Open Access
158 Citations
25,743 Views
31 Pages

16 December 2021

Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuat...

  • Article
  • Open Access
2 Citations
1,843 Views
13 Pages

Dynamic Changes in Viral Loads during Co-Infection with a Recombinant Turkey Herpesvirus Vector Vaccine and Very Virulent Marek’s Disease Virus In Vivo

  • Tian Ding,
  • Min Xiong,
  • Yang Xu,
  • Xing Pu,
  • Qin-sen Wang,
  • Mo-ru Xu,
  • Hong-xia Shao,
  • Kun Qian,
  • Hai-bin Dang and
  • Ai-jian Qin

27 June 2024

Marek’s disease (MD), caused by the Marek’s disease virus (MDV), is a common infectious tumor disease in chickens and was the first neoplastic disease preventable by vaccination. However, the vaccine cannot completely prevent virulent MDV...

  • Article
  • Open Access
18 Citations
12,053 Views
17 Pages

18 March 2015

Gene-based vaccines as typified by plasmid DNA vaccines and recombinant viral-vectored vaccines are expected as promising solutions against infectious diseases for which no effective prophylactic vaccines exist such as HIV, dengue virus, Ebola virus...

  • Review
  • Open Access
78 Citations
11,625 Views
30 Pages

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

  • Vivek P. Chavda,
  • Rajashri Bezbaruah,
  • Disha Valu,
  • Bindra Patel,
  • Anup Kumar,
  • Sanjay Prasad,
  • Bibhuti Bhusan Kakoti,
  • Ajeet Kaushik and
  • Mariya Jesawadawala

13 February 2023

The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determi...

  • Review
  • Open Access
35 Citations
4,683 Views
20 Pages

Current Vaccine Platforms in Enhancing T-Cell Response

  • Takehiro Ura,
  • Masaki Takeuchi,
  • Tatsukata Kawagoe,
  • Nobuhisa Mizuki,
  • Kenji Okuda and
  • Masaru Shimada

21 August 2022

The induction of T cell-mediated immunity is crucial in vaccine development. The most effective vaccine is likely to employ both cellular and humoral immune responses. The efficacy of a vaccine depends on T cells activated by antigen-presenting cells...

  • Article
  • Open Access
9 Citations
4,941 Views
15 Pages

Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine

  • MD Faizul Hussain Khan,
  • Maryam Youssef,
  • Sean Nesdoly and
  • Amine A. Kamen

11 June 2024

The thermostability of vaccines, particularly enveloped viral vectored vaccines, remains a challenge to their delivery wherever needed. The freeze-drying of viral vectored vaccines is a promising approach but remains challenging due to the water remo...

  • Review
  • Open Access
562 Views
20 Pages

Potential of Bovine Herpesvirus Vectors for Recombinant Vaccines

  • Eda Mert Gokduman,
  • Mustafa Ozan Atasoy,
  • Ayşe Gencay Goksu,
  • İbrahim Sozdutmaz and
  • Muhammad Munir

20 December 2025

The livestock industry experiences significant economic losses as a result of viral infections. Building on recent advances in biotechnological research, recombinant viral vector vaccines have emerged as promising platforms for next-generation vaccin...

  • Feature Paper
  • Article
  • Open Access
29 Citations
17,934 Views
23 Pages

Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis

  • Rafael G. Ferreira,
  • Neal F. Gordon,
  • Rick Stock and
  • Demetri Petrides

18 August 2021

The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several of these successful vaccines are based on the adenoviral vector platform. The mass manufacturing of these vaccines p...

  • Article
  • Open Access
1,619 Views
12 Pages

Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein

  • Debora Patricia Garanzini,
  • Matias Ariel Micucci,
  • Annalies Torres Lopez,
  • Oscar Perez,
  • Gabriela Calamante and
  • Maria Paula Del Medico Zajac

27 March 2025

Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficie...

of 16